Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 31, Issue 3, pp 326–343 | Cite as

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

  • Edith Nutescu
  • Ittiporn Chuatrisorn
  • Erika Hellenbart
Article

Abstract

Clinicians and patients around the world have been intrigued by the concept of developing an oral anticoagulant with a broad therapeutic window and few drug and dietary interactions that can be administered at fixed doses with no or minimal monitoring. The recently approved oral direct thrombin inhibitor dabigatran, along with the emerging oral anti-factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have been developed to address many of the shortcomings of warfarin therapy. As warfarin is associated with extensive food and drug interactions, there is also a need to consider such interactions with the new oral anticoagulants. While to date few drug and dietary interactions have been reported with the new oral anticoagulants, it is still early in their development and clinical use cycle. Pharmacokinetic and pharmacodynamic profiles will have to be closely accounted for when determining the likelihood of a potential drug interaction prior to therapy initiation. As the list of drugs and supplements that interact with warfarin is continuously expanding, and the knowledge on drug interactions with the novel oral anticoagulants is still in its infancy, clinicians need to be vigilant when initiating any of these agents or when any changes in the patient’s medication profile occur and perform a close screening for potential drug and dietary interactions. The objective of this paper is to give an update on drug and dietary interactions with warfarin and the novel oral anticoagulants, dabigatran, rivaroxaban, apixaban, and edoxaban.

Keywords

Warfarin Novel oral anticoagulants Drug interactions Dietary interactions Dabigatran Rivaroxaban Apixaban Edoxaban 

References

  1. 1.
    Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167(13):1414–1419PubMedGoogle Scholar
  2. 2.
    Wysowski DK (2007) Surveillance of prescription drug-related mortality using death certificate data. Drug Saf 30(6):533–540PubMedGoogle Scholar
  3. 3.
    Tadros R, Shakib S (2010) Warfarin—indications, risks and drug interactions. Aust Fam Physician 39(6):476–479PubMedGoogle Scholar
  4. 4.
    Holbrook AM et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095–1106PubMedGoogle Scholar
  5. 5.
    Errick JK, Keys PW (1978) Co-trimoxazole and warfarin: case report of an interaction. Am J Hosp Pharm 35(11):1399–1401PubMedGoogle Scholar
  6. 6.
    Greenlaw CW (1979) Drug interaction between co-trimoxazole and warfarin. Am J Hosp Pharm 36(9):1155–1156PubMedGoogle Scholar
  7. 7.
    Fredriks DA (1989) Comment: TMP/SMX—warfarin interaction. DICP 23(7–8):619–620PubMedGoogle Scholar
  8. 8.
    Cook DE, Ponte CD (1994) Suspected trimethoprim/sulfamethoxazole-induced hypoprothrombinemia. J Fam Pract 39(6):589–591PubMedGoogle Scholar
  9. 9.
    Chafin CC et al (2000) Hospital admission due to warfarin potentiation by TMP-SMX. Nurse Pract 25(12):73–75PubMedGoogle Scholar
  10. 10.
    Ahmed A et al (2008) Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Thromb Thrombolysis 26(1):44–48PubMedGoogle Scholar
  11. 11.
    Fischer HD et al (2010) Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 170(7):617–621PubMedGoogle Scholar
  12. 12.
    Seaton TL, Celum CL, Black DJ (1990) Possible potentiation of warfarin by fluconazole. DICP 24(12):1177–1178PubMedGoogle Scholar
  13. 13.
    Crussell-Porter LL et al (1993) Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 153(1):102–104PubMedGoogle Scholar
  14. 14.
    Kerr HD (1993) Case report: potentiation of warfarin by fluconazole. Am J Med Sci 305(3):164–165PubMedGoogle Scholar
  15. 15.
    Baciewicz AM et al (1994) Fluconazole–warfarin interaction. Ann Pharmacother 28(9):1111PubMedGoogle Scholar
  16. 16.
    Kunze KL et al (1996) Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24(4):414–421PubMedGoogle Scholar
  17. 17.
    Allison EJ Jr, McKinney TJ, Langenberg JN (2002) Spinal epidural haematoma as a result of warfarin/fluconazole drug interaction. Eur J Emerg Med 9(2):175–177PubMedGoogle Scholar
  18. 18.
    Mootha VV, Schluter ML, Das A (2002) Intraocular hemorrhages due to warfarin fluconazole drug interaction in a patient with presumed Candida endophthalmitis. Arch Ophthalmol 120(1):94–95PubMedGoogle Scholar
  19. 19.
    Turrentine MA (2006) Single-dose fluconazole for vulvovaginal candidiasis: impact on prothrombin time in women taking warfarin. Obstet Gynecol 107(2 Pt 1):310–313PubMedGoogle Scholar
  20. 20.
    Kazmier FJ (1976) A significant interaction between metronidazole and warfarin. Mayo Clin Proc 51(12):782–784PubMedGoogle Scholar
  21. 21.
    O’Reilly RA (1976) The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 295(7):354–357PubMedGoogle Scholar
  22. 22.
    Yacobi A, Lai CM, Levy G (1984) Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin enantiomers and metronidazole in rats. J Pharmacol Exp Ther 231(1):72–79PubMedGoogle Scholar
  23. 23.
    Howard-Thompson A et al (2008) Intracerebral hemorrhage secondary to a warfarin–metronidazole interaction. Am J Geriatr Pharmacother 6(1):33–36PubMedGoogle Scholar
  24. 24.
    Long E (1983) Warfarin–miconazole interaction. Arch Intern Med 143(11):2214–2215PubMedGoogle Scholar
  25. 25.
    Colquhoun MC et al (1987) Interaction between warfarin and miconazole oral gel. Lancet 1(8534):695–696PubMedGoogle Scholar
  26. 26.
    Shenfield GM, Page M (1991) Potentiation of warfarin action by miconazole oral gel. Aust N Z J Med 21(6):928PubMedGoogle Scholar
  27. 27.
    Pillans P, Woods DJ (1996) Interaction between miconazole oral gel (Daktarin) and warfarin. N Z Med J 109(1029):346PubMedGoogle Scholar
  28. 28.
    Ariyaratnam S et al (1997) Potentiation of warfarin anticoagulant activity by miconazole oral gel. BMJ 314(7077):349PubMedGoogle Scholar
  29. 29.
    Ezsias A, Wojnarowska F, Juniper R (1997) Topical use of miconazole antifungal oral gel on warfarinized patients: a word of caution. Dent Update 24(10):421–422PubMedGoogle Scholar
  30. 30.
    Pemberton MN et al (1998) Derangement of warfarin anticoagulation by miconazole oral gel. Br Dent J 184(2):68–69PubMedGoogle Scholar
  31. 31.
    Silingardi M et al (2000) Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost 83(5):794–795PubMedGoogle Scholar
  32. 32.
    Thirion DJ, Zanetti LA (2000) Potentiation of warfarin’s hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy 20(1):98–99PubMedGoogle Scholar
  33. 33.
    Murty M (2001) Miconazole–warfarin interaction: increased INR. CMAJ 165(1): pp 81–82, 85–86Google Scholar
  34. 34.
    Devaraj A et al (2002) Interaction between warfarin and topical miconazole cream. BMJ 325(7355):77PubMedGoogle Scholar
  35. 35.
    Pemberton MN, Oliver RJ, Theaker ED (2004) Miconazole oral gel and drug interactions. Br Dent J 196(9):529–531PubMedGoogle Scholar
  36. 36.
    Miki A, Ohtani H, Sawada Y (2010) Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model. J Clin Pharm Ther [Epub ahead of print]Google Scholar
  37. 37.
    Thomas JL et al (2010) Hyperprothrombinemia as a result of a possible warfarin and intravaginal miconazole interaction. South Med J 103(10):1063–1065PubMedGoogle Scholar
  38. 38.
    Purkins L et al (2003) Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 56(Suppl 1):24–29PubMedGoogle Scholar
  39. 39.
    Chock AW, Stading JA (2006) Indeterminable international normalized ratio with concurrent use of warfarin and gatifloxacin. Am J Health Syst Pharm 63(16):1539–1542PubMedGoogle Scholar
  40. 40.
    Mathews S, Cole J, Ryono RA (2006) Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin. Pharmacotherapy 26(10):1446–1452PubMedGoogle Scholar
  41. 41.
    Glasheen JJ, Prochazka AV (2007) The safety of levofloxacin in patients on warfarin. Am J Med 120(4):e13 author reply e15–6PubMedGoogle Scholar
  42. 42.
    Mercadal Orfila G et al (2009) Retrospective assessment of potential interaction between levofloxacin and warfarin. Pharm World Sci 31(2):224–229PubMedGoogle Scholar
  43. 43.
    Vadlamudi RS, Smalligan RD, Ismail HM (2007) Interaction between warfarin and levofloxacin: case series. South Med J 100(7):720–724PubMedGoogle Scholar
  44. 44.
    Washington C et al (2007) Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. J Clin Pharmacol 47(10):1320–1326PubMedGoogle Scholar
  45. 45.
    Carroll DN, Carroll DG (2008) Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother 42(5):680–685PubMedGoogle Scholar
  46. 46.
    Glasheen JJ, Prochazka AV (2008) Further evidence of a clinically significant levofloxacin–warfarin interaction. South Med J 101(6):660 author reply 660PubMedGoogle Scholar
  47. 47.
    Schelleman H et al (2008) Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 84(5):581–588PubMedGoogle Scholar
  48. 48.
    Zhang K, Young C, Berger J (2006) Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug–drug and drug–disease interactions. J Manag Care Pharm 12(8):640–648PubMedGoogle Scholar
  49. 49.
    FDA U.S. Food and Drug Administration. MedWatch The FDA Safety Information and Adverse Event Reporting Program. Drug safety labeling changes. Zithromax (azithromycin) IV, February 2009 [cited 23 Dec 2010]; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm133120.htm
  50. 50.
    Foster DR, Milan NL (1999) Potential interaction between azithromycin and warfarin. Pharmacotherapy 19(7):902–908PubMedGoogle Scholar
  51. 51.
    Lane G (1996) Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin. Ann Pharmacother 30(7–8):884–885PubMedGoogle Scholar
  52. 52.
    Rao KB et al (2004) Enhanced hypoprothrombinemia with warfarin due to azithromycin. Ann Pharmacother 38(6):982–985PubMedGoogle Scholar
  53. 53.
    Shrader SP, Fermo JD, Dzikowski AL (2004) Azithromycin and warfarin interaction. Pharmacotherapy 24(7):945–949PubMedGoogle Scholar
  54. 54.
    Woldtvedt BR et al (1998) Possible increased anticoagulation effect of warfarin induced by azithromycin. Ann Pharmacother 32(2):269–270PubMedGoogle Scholar
  55. 55.
    Malek J et al (2010) Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med [Epub ahead of print]Google Scholar
  56. 56.
    Liedtke MD, Rathbun RC (2010) Drug interactions with antiretrovirals and warfarin. Expert Opin Drug Saf 9(2):215–223PubMedGoogle Scholar
  57. 57.
    Fulco PP, Zingone MM, Higginson RT (2008) Possible antiretroviral therapy–warfarin drug interaction. Pharmacotherapy 28(7):945–949PubMedGoogle Scholar
  58. 58.
    Liedtke MD, Rathbun RC (2009) Warfarin–antiretroviral interactions. Ann Pharmacother 43(2):322–328PubMedGoogle Scholar
  59. 59.
    Dionisio D et al (2001) Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 15(2):277–278PubMedGoogle Scholar
  60. 60.
    von Moltke LL et al (2001) Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 41(1):85–91Google Scholar
  61. 61.
    Bonora S et al (2008) Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 46(1):146–147PubMedGoogle Scholar
  62. 62.
    Gatti G et al (1998) Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 12(7):825–826PubMedGoogle Scholar
  63. 63.
    Knoell KR, Young TM, Cousins ES (1998) Potential interaction involving warfarin and ritonavir. Ann Pharmacother 32(12):1299–1302PubMedGoogle Scholar
  64. 64.
    Hughes CA, Freitas A, Miedzinski LJ (2007) Interaction between lopinavir/ritonavir and warfarin. CMAJ 177(4):357–359PubMedGoogle Scholar
  65. 65.
    Newshan G, Tsang P (1999) Ritonavir and warfarin interaction. AIDS 13(13):1788–1789PubMedGoogle Scholar
  66. 66.
    Darlington MR (1997) Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir. Ann Pharmacother 31(5):647PubMedGoogle Scholar
  67. 67.
    Ward S et al (2007) A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11(14): pp 1–160, iii–ivGoogle Scholar
  68. 68.
    Robinson JG, Booth B (2010) Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 4(6):483–490PubMedGoogle Scholar
  69. 69.
    Andrus MR (2004) Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 24(2):285–290PubMedGoogle Scholar
  70. 70.
    Schelleman H et al (2010) Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 123(2):151–157PubMedGoogle Scholar
  71. 71.
    Barry M (2004) Rosuvastatin–warfarin drug interaction. Lancet 363(9405):328PubMedGoogle Scholar
  72. 72.
    Hickmott H, Wynne H, Kamali F (2003) The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 89(5):949–950PubMedGoogle Scholar
  73. 73.
    Lin JC et al (1999) The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 39(1):86–90PubMedGoogle Scholar
  74. 74.
    Williams D, Feely J (2002) Pharmacokinetic–pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41(5):343–370PubMedGoogle Scholar
  75. 75.
    Westergren T, Johansson P, Molden E (2007) Probable warfarin–simvastatin interaction. Ann Pharmacother 41(7):1292–1295PubMedGoogle Scholar
  76. 76.
    Kassebaum PJ, Shaw DL, Tomich DJ (2005) Possible warfarin interaction with menthol cough drops. Ann Pharmacother 39(2):365–367PubMedGoogle Scholar
  77. 77.
    Coderre K, Faria C, Dyer E (2010) Probable warfarin interaction with menthol cough drops. Pharmacotherapy 30(1):110PubMedGoogle Scholar
  78. 78.
    Dresser GK et al (2002) Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 72(3):247–255PubMedGoogle Scholar
  79. 79.
    Ni H, Simile C, Hardy AM (2002) Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 40(4):353–358PubMedGoogle Scholar
  80. 80.
    Tindle HA et al (2005) Trends in use of complementary and alternative medicine by US adults: 1997–2002. Altern Ther Health Med 11(1):42–49PubMedGoogle Scholar
  81. 81.
    Elmer GW et al (2007) Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Ann Pharmacother 41(10):1617–1624PubMedGoogle Scholar
  82. 82.
    Leung VW et al (2009) Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin. Ann Pharmacother 43(5):875–881PubMedGoogle Scholar
  83. 83.
    Smith L et al (2004) Co-ingestion of herbal medicines and warfarin. Br J Gen Pract 54(503):439–441PubMedGoogle Scholar
  84. 84.
    Taylor DM et al (2006) Potential interactions between prescription drugs and complementary and alternative medicines among patients in the emergency department. Pharmacotherapy 26(5):634–640PubMedGoogle Scholar
  85. 85.
    MHRA/CSM (2004) Interaction between warfarin and cranberry juice: new advice. Curr Probl Pharmacovig 30:10Google Scholar
  86. 86.
    Suvarna R, Pirmohamed M, Henderson L (2003) Possible interaction between warfarin and cranberry juice. BMJ 327(7429):1454PubMedGoogle Scholar
  87. 87.
    Grant P (2004) Warfarin and cranberry juice: an interaction? J Heart Valve Dis 13(1):25–26PubMedGoogle Scholar
  88. 88.
    Rindone JP, Murphy TW (2006) Warfarin–cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. Am J Ther 13(3):283–284PubMedGoogle Scholar
  89. 89.
    Paeng CH, Sprague M, Jackevicius CA (2007) Interaction between warfarin and cranberry juice. Clin Ther 29(8):1730–1735PubMedGoogle Scholar
  90. 90.
    Mergenhagen KA, Sherman O (2008) Elevated International Normalized Ratio after concurrent ingestion of cranberry sauce and warfarin. Am J Health Syst Pharm 65(22):2113–2116PubMedGoogle Scholar
  91. 91.
    Welch JM, Forster K (2007) Probable elevation in international normalized ratio from cranberry juice. J Pharm Technol 23:4Google Scholar
  92. 92.
    Greenblatt DJ et al (2006) Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther 79(1):125–133PubMedGoogle Scholar
  93. 93.
    Mohammed Abdul MI, Jiang X, Williams KM (2008) A randomized, double-blind trial of the interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 154(8):1691–1700PubMedGoogle Scholar
  94. 94.
    Ansell J et al (2009) The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. J Clin Pharmacol 49(7):824–830PubMedGoogle Scholar
  95. 95.
    Mellen CK, Ford M, Rindone JP (2010) Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients. Br J Clin Pharmacol 70(1):139–142PubMedGoogle Scholar
  96. 96.
    Li Z et al (2006) Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 106(12):2057–2061PubMedGoogle Scholar
  97. 97.
    Zikria J, Goldman R, Ansell J (2010) Cranberry juice and warfarin: when bad publicity trumps science. Am J Med 123:384–392PubMedGoogle Scholar
  98. 98.
    Cheng TO (2007) Green tea may inhibit warfarin. Int J Cardiol 115(2):236PubMedGoogle Scholar
  99. 99.
    Taylor JR, Wilt VM (1999) Probable antagonism of warfarin by green tea. Ann Pharmacother 33(4):426–428PubMedGoogle Scholar
  100. 100.
    Chan HT et al (2010) Effect of herbal consumption on clinical efficacy of warfarin therapy in patients with atrial fibrillation. Eur Heart J 31(Supplement 1):2Google Scholar
  101. 101.
    Booth SL et al (1995) Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone). J Am Diet Assoc 95(1):82–83PubMedGoogle Scholar
  102. 102.
    Shord SS, Shah K, Lukose A (2009) Drug–botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther 8(3):208–227PubMedGoogle Scholar
  103. 103.
    Connolly SJ et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151PubMedGoogle Scholar
  104. 104.
    Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47(5):285–295PubMedGoogle Scholar
  105. 105.
    Blech S et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36(2):386–399PubMedGoogle Scholar
  106. 106.
    Stangier J et al (2008) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48(12):1411–1419PubMedGoogle Scholar
  107. 107.
    Stangier J et al (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259–268PubMedGoogle Scholar
  108. 108.
    U.S. FDA (2010) Label and approval history for PRADAXA, NDA no. 022512. 2010 [cited 20 Dec 2010]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf
  109. 109.
    Stangier J et al (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45(5):555–563PubMedGoogle Scholar
  110. 110.
    Stangier J et al (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47(1):47–59PubMedGoogle Scholar
  111. 111.
    Stangier J et al (2007) No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin (Abstracts). Thromb Haemost 5(Supplement 2):P-W_672Google Scholar
  112. 112.
    Stangier J et al (2009) Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 9(1):59–68PubMedGoogle Scholar
  113. 113.
    US Department of Health and Human Services. US Food and Drug Administration. Briefing Information for the March 19, 2009 Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm138368.htm. Accessed Jan 2011
  114. 114.
    Kubitza D et al (2006) Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin. J Clin Pharmacol 46(9):981–990PubMedGoogle Scholar
  115. 115.
    Samama MM (2010) The mechanism of action of rivaroxaban—an oral, direct Factor Xa inhibitor—compared with other anticoagulants. Thromb Res [Epub ahead of print]Google Scholar
  116. 116.
    Perzborn E et al (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 10(1):61–75PubMedGoogle Scholar
  117. 117.
    Kubitza D et al (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70(5):703–712PubMedGoogle Scholar
  118. 118.
    Kubitza D et al (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46(5):549–558PubMedGoogle Scholar
  119. 119.
    Xarelto: summary of product characteristics (2010). Bayer Schering Pharma. www.Xarelto.com
  120. 120.
    Perzborn E, Fischer E, Lange U (2007) Combination rivaroxaban with acethylsalicylic acid increased antithrombotic potency without affect bleeding times in animal model. J Thromb Haemost 5(Supplement 2), Abstract P-W-639Google Scholar
  121. 121.
    Kubitza D et al (2007) Rivaroxaban (BAY 59–7939)—an oral, direct Factor Xa inhibitor—has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 63(4):469–476PubMedGoogle Scholar
  122. 122.
    Frost C, Yu Z, Moore K (2007) Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Supplement 2), Abstract P-M-664Google Scholar
  123. 123.
    Shantsila E, Lip GY (2008) Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs 9(9):1020–1033PubMedGoogle Scholar
  124. 124.
    Raghavan N et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37(1):74–81PubMedGoogle Scholar
  125. 125.
    Wang L et al (2010) In vitro assessment of metabolic drug–drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38(3):448–458PubMedGoogle Scholar
  126. 126.
    Huang J et al (2010) Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 105(2):245–253PubMedGoogle Scholar
  127. 127.
    Lassen MR et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717):807–815PubMedGoogle Scholar
  128. 128.
    Frost C (2008) Food does not affect the pharmacokinetics of apixaban, an oral factor Xa inhibitor. In: IXth World Conference on Clinical Pharmacology and Therapeutics. Quebec City, Canada, T2M061Google Scholar
  129. 129.
    Carreiro J, Ansell J (2008) Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 17(12):1937–1945PubMedGoogle Scholar
  130. 130.
    Frost C, Lee L, Li L (2007) Apixaban does not affect the pharmacokinetics of digoxin. J Clin Pharmacol 47(9):1196, Abstract # 60Google Scholar
  131. 131.
    Wong PC, Jiang X (2010) Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 104(2):302–310PubMedGoogle Scholar
  132. 132.
    Alexander JH et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119(22):2877–2885PubMedGoogle Scholar
  133. 133.
    Ogata K et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50(7):743–753PubMedGoogle Scholar
  134. 134.
    Furugohri T et al (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6(9):1542–1549PubMedGoogle Scholar
  135. 135.
    Morishima Y et al (2007) Activated prothrombin complex concentrate, recombinant factor VIII and factor IX reverse prolong clotting time induced by DU-712b, a direct factor Xa inhibitor, in human plasma. J Thromb Haemost 5(Supplement 2), Abstract P-T-639Google Scholar
  136. 136.
    Mendell J et al (2010) Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol [Epub ahead of print]Google Scholar
  137. 137.
    Hasan SA (2007) Interaction of doxycycline and warfarin: an enhanced anticoagulant effect. Cornea 26(6):742–743PubMedGoogle Scholar
  138. 138.
    McCall KL, Scott JC, Anderson HG (2005) Retrospective evaluation of a possible interaction between warfarin and levofloxacin. Pharmacotherapy 25(1):67–73PubMedGoogle Scholar
  139. 139.
    Arnold LM, Nissen LR, Ng TM (2005) Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction. Pharmacotherapy 25(6):904–907PubMedGoogle Scholar
  140. 140.
    Anthony M et al (2009) Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther 86(4):425–429PubMedGoogle Scholar
  141. 141.
    Dixon DL, Williams VG (2009) Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 29(6):744–748PubMedGoogle Scholar
  142. 142.
    Simonson SG et al (2005) Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 45(8):927–934PubMedGoogle Scholar
  143. 143.
    Battistella M et al (2005) Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 165(2):189–192PubMedGoogle Scholar
  144. 144.
    Yeh RF et al (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42(1):52–60PubMedGoogle Scholar
  145. 145.
    Glueck CJ et al (2006) Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA 295(13):1517–1518PubMedGoogle Scholar
  146. 146.
    Kurdyak PA et al (2005) Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 25(6):561–564PubMedGoogle Scholar
  147. 147.
    Yamreudeewong W et al (2009) Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 43(7):1347–1353PubMedGoogle Scholar
  148. 148.
    Uno T et al (2008) The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 30(3):276–281PubMedGoogle Scholar
  149. 149.
    Nakajima M et al (2010) Increased anticoagulant activity of warfarin used in combination with doxifluridine. Cancer Chemother Pharmacol 66(5):969–972PubMedGoogle Scholar
  150. 150.
    Min KA et al (2006) Effect of oxolamine on anticoagulant effect of warfarin. Am J Health Syst Pharm 63(2):153–156PubMedGoogle Scholar
  151. 151.
    Nutescu EA et al (2006) Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 5(3):433–451PubMedGoogle Scholar
  152. 152.
    Rupprecht HJ, Blank R (2010) Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs 70(16):2153–2170PubMedGoogle Scholar
  153. 153.
    Ufer M (2010) Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 103(3):572–585PubMedGoogle Scholar
  154. 154.
    Wittkowsky AK (2010) New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 29(2):182–191PubMedGoogle Scholar
  155. 155.
    Pradaxa™ (Dabigatran Etexilate) (2010) Product Information.www.pradaxa.com

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Edith Nutescu
    • 1
    • 2
  • Ittiporn Chuatrisorn
    • 3
  • Erika Hellenbart
    • 4
    • 5
  1. 1.Department of Pharmacy Practice and Center for Pharmacoeconomic ResearchUniversity of Illinois at Chicago, College of PharmacyChicagoUSA
  2. 2.Antithrombosis CenterUniversity of Illinois Medical Center at ChicagoChicagoUSA
  3. 3.Department of Pharmacy Practice, Faculty of Pharmaceutical ScienceChulalongkorn UniversityBangkokThailand
  4. 4.University of Illinois Medical Center at ChicagoChicagoUSA
  5. 5.University of Illinois at Chicago, College of PharmacyChicagoUSA

Personalised recommendations